By Jocelyn Aspa
Infinity Pharmaceuticals, Sorrento Therapeutics, CASI Pharmaceuticals, KalVista Pharmaceuticals, and Prima BioMed topped last week’s NASDAQ biotech stock list.
Zogenix, Aradigm, Vermillion, Aralez Pharmaceuticals and Kura Oncology top the NASDAQ biotech stock list.
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
Voyager Therapeutics announced positive results from their ongoing Phase 1b trial of VY-AADC01 in advanced Parkinson’s disease.
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.
Abeona Therapeutics announced the US Food and Drug Administration granted a Breakthrough Therapy designation status to the company’s EB-101 gene therapy program.
Delcath Systems, MannKind, Zogenix, BioLife Solutions and BioDelivery Sciences top the NASDAQ biotech stock list.
Abeona Therapeutics announced an expansion to its gene therapy clinical trials for patients with MPS IIIA in the US, Europe, and Australia.
Fortress Biotech announced the creation of a new subsidiary called Aevitas Therapeutics.
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
uniQure will regain the rights for their hemophilia B gene therapy as the Chiesi Group backs out from working partnership with the genetics company.
Doug Casey, Brent Cook, Adrian Day, Matt Badiali, Keith Fitz-Gerald, Chris Gaffney and Byron King discuss their investment ideas and top stock picks for 2017.